RxDoctor Payments Data

Linda Ferrer, MD

Cardiovascular Disease · Kearney, NENPI 1295113439

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $3,886 of the $5,943 with a category attached, or 65.4%. 23 manufacturers reported payments, led by Boston Scientific at 34.6% of the total.

$5,943in general payments, 2019–2025

Across 112 payments — averaging $53.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Edwards Lifesciences$2K
  • Medtronic$838
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$455
  • AstraZeneca$197
  • Astellas Pharma US Inc$180
  • plus $581 from 17 others

What the payments were for

  • Travel & lodging$3,88665%
  • Food & beverage$1,89332%
  • Education$1643%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,943 in reported general payments places this provider in the 70th percentile of 97 cardiovascular disease providers in Nebraska.

See all cardiovascular disease providers in Nebraska

Medicare billing

Part B allowed, 2024
$194,295
Medicare patients
1,069
Services billed
3,869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban263$182,433
XareltoRivaroxaban145$126,056
EntrestoSacubitril/Valsartan115$53,365
MultaqDronedarone Hcl32$38,005
JardianceEmpagliflozin51$33,303
BrilintaTicagrelor26$13,691
Repatha SureclickEvolocumab11$5,867
Potassium Chloride370$5,087
Bumetanide286$5,005
Metoprolol Succinate441$4,656
Atorvastatin Calcium437$3,780
Pitavastatin Calcium15$3,136
Ranolazine ErRanolazine59$3,055
Bisoprolol Fumarate101$2,128
Amlodipine Besylate231$2,038

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$182,433263 claims
Johnson & JohnsonXarelto$34$126,056145 claims
NovartisEntresto$42$53,365115 claims
Sanofi-aventis U.S. LLCMultaq$39$38,00532 claims
Boehringer IngelheimJardiance$30$33,30351 claims
AstraZenecaBrilinta$197$13,69126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 97 cardiovascular disease providers in Nebraska.

Other cardiovascular disease in Kearney

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →